Fujairah Hospital, United Arab Emirates.Background: Metabolic Syndrome (MetS) is a highly prevalent condition among patients with acute myocardial infarction (AMI) in the intensive care unit (ICU), yet its direct impact on in- hospital outcomes remain a subject of debate. This systematic review aims to synthesize the current evidence on the prevalence of MetS in critically ill AMI patients and its association with clinical severity and in-hospital mortality. Methods: This is a systematic observational study. Data on patients’ demographics, clinical characteristics, and clinical outcomes were systematically extracted and synthesized. The study focused on prevalence rates, patient characteristics including age, gender, body mass index, waist circumference, and comorbidities, as well as in-hospital outcomes such as mortality, heart failure, and major adverse cardiovascular events. Results: The prevalence of MetS in patients with AMI in the ICU setting is consistently high, ranging from 46% to 68.3% across different populations [1, 2]. Patients with MetS are more likely to be female and present with a higher body mass index (BMI), larger waist circumference, and a greater incidence of hypertension and diabetes. While some studies report no significant increase in all-cause in-hospital mortality, others indicate a significantly higher rate of cardiovascular mortality (P = .03) and an increased risk of complications such as congestive heart failure and recurrent myocardial ischemia [1, 3]. Specific components of MetS, notably hyperglycemia and a BMI ≥28 kg/m², have been identified as independent predictors of major adverse cardiovascular events (MACE) [2]. The pathophysiological mechanisms underlying these outcomes demonstrate the complex interplay between MetS components and myocardial dysfunction. Conclusion: Metabolic Syndrome is a major health burden in critically ill patients with AMI, associated with a higher risk of specific in-hospital complications, even if its role in all- cause mortality is not definitively established. The underlying pathophysiology involves a complex interplay of systemic inflammation, endothelial dysfunction, and a prothrombotic state, which collectively drive myocardial fibrosis and ventricular hypertrophy, culminating in myocardial dysfunction. These findings underscore the critical need for early identification and aggressive management of MetS and its components to improve outcomes in this high-risk population. Further large-scale prospective studies are warranted to clarify the prognostic implications of MetS in the ICU.
The traditional paradigm of dentistry as a localized surgical discipline is being replaced by a model of systemic preventative medicine. Recent evidence confirms that the oral microbiome serves as a reservoir for systemic inflammation, directly influencing the pathogenesis of atherosclerotic cardiovascular disease (ASCVD) and heart failure. This article explores the integration of smart dental implants for real-time biomarker sensing, AI-driven teledentistry for predictive risk assessment, and oral-derived stem cells for myocardial regeneration. This convergence marks the transition to "Oral-Cardiology," a field where the oral cavity is the primary diagnostic and therapeutic gateway for cardiovascular health.
Background: The interdependence of oral health and cardiovascular stability represents a critical frontier in interdisciplinary medicine. For patients undergoing major cardiovascular interventions such as Coronary Artery Bypass Graft (CABG) or Heart Valve Replacement, the oral cavity serves as a significant potential reservoir for opportunistic pathogens that may precipitate life-threatening complications. Objectives: To delineate the pathophysiological "Oral-Cardiac Axis" and provide a standardized clinical protocol for Pre-operative Dental Clearance (PDC) that integrates contemporary evidence on systemic inflammatory markers, molecular mimicry, and odontogenic bacteremia. Methods: This comprehensive review synthesizes current evidence regarding systemic inflammatory markers (CRP, IL-6), molecular mimicry mechanisms, and the impact of odontogenic bacteremia on surgical outcomes through systematic analysis of clinical studies and mechanistic research. Results: Chronic periodontitis and periapical pathology are independently associated with increased post-operative morbidity, including prosthetic valve endocarditis (PVE) and systemic inflammatory response syndrome (SIRS). The molecular mechanisms involve complex pathways including systemic inflammation, oxidative stress, molecular mimicry, and bacterial translocation. While evidence for routine dental clearance shows mixed results, targeted intervention based on inflammatory burden assessment may optimize outcomes. Conclusions: Dentists serve as essential clinical co-investigators in cardiology, and standardized dental clearance protocols represent a crucial component of comprehensive cardiovascular surgical preparation. The integration of oral health assessment within multidisciplinary cardiac care teams represents a paradigm shift toward truly holistic patient management.
Peripartum cardiomyopathy (PPCM) is an idiopathic systolic heart failure syndrome occurring in late pregnancy or the early postpartum period in the absence of pre-existing structural heart disease. Once considered a rare obstetric complication, PPCM is now recognized as a heterogeneous cardiomyopathy arising from the interplay of pregnancy-related vascular stress and underlying myocardial vulnerability. This narrative review summarizes current evidence on epidemiology, pathophysiology, clinical presentation, imaging, management, and long-term outcomes. Contemporary mechanistic models emphasize angiogenic imbalance, prolactin cleavage, oxidative stress, inflammation, and genetic susceptibility as central contributors to myocardial dysfunction. Clinical presentation ranges from mild heart failure symptoms to cardiogenic shock, ventricular arrhythmias, and thromboembolism. Echocardiography remains the diagnostic cornerstone, while strain imaging and cardiac magnetic resonance provide additional phenotypic and prognostic insight. Recovery is highly variable; although many women demonstrate substantial improvement within 6–12 months, a significant proportion develop persistent left ventricular dysfunction with long-term implications. Baseline ventricular function and early recovery trajectory are key determinants of outcome. Management requires pregnancy-adapted heart failure therapy, structured follow-up, and multidisciplinary cardio-obstetric care. Future efforts should prioritize phenotype-driven strategies, optimized risk stratification, and large collaborative registries to refine precision management in PPCM.
This case report describes the endovascular treatment of a 77-year-old man with concomitant abdominal aortic and left popliteal artery aneurysms. The patient presented with abdominal pain and a pulsatile mass in the left popliteal fossa. Imaging revealed a fusiform infrarenal aortic aneurysm and a popliteal artery aneurysm, along with significant stenosis of the superficial femoral artery. The aortic aneurysm was treated with a standard bifurcated endograft. The popliteal aneurysm was excluded using two Wrapsody™ stent grafts. At six-month follow-up, both aneurysms remained excluded and the stents were patent. This case highlights the potential off-label use of the Wrapsody™ stent graft in peripheral arteries, particularly when flexibility and radial strength are required. The device may offer a feasible alternative when conventional arterial stent grafts are not suitable or available.
Aim: This study aimed to evaluate impact of percutaneous coronary intervention (PCI) in management and prognosis of acute coronary syndromes in Ouagadougou. Methods: An analytic study compared data from two registries: the myocardial Infarction registry of Ouagadougou (RIO) before PCI and the Interventional Cardiology Registry of Burkina Faso (RE.C. I-Burkina) in the era of PCI. It included patients aged more than 18 years admitted for acute coronary syndromes (ACS) in Ouagadougou. Sociodemographic, clinical, therapeutic characteristics and outcomes of the patients of the two registries were analyzed. Results: 343 patients were included. Patients of RE.C. I-Burkina registry were younger than them of RIO registry (p=0.011). ACS was dominated by STEMI in both registries. In RE.C. I-Burkina coronary lesions were multivessel in 74%. PCI was performed in 55,9% of patients who underwent coronary angiography with successful procedure in 92,1% of cases. In hospital mortality in the RE.C.I.-Burkina registry was lower than that in the RIO registry (5,9% vs 12.7%, p=0.011). Conclusion: PCI improved coronary revascularization rate and hospital mortality from ACS in Burkina Faso. These results should be better by earlier cares and team improvement.
Introduction : The atrioventricular block (AV Block) is a normal loss of function of the cardiac conduction pathway between the atrium and the ventricle. It is a serious pathology encountered throughout the world, whose management mainly involves cardiac stimulation. This study aimed to describe the practice of cardiac stimulation in Guinea. Methodology: It was a cross-sectional descriptive study lasting 22 months from November 1, 2023, to August 30, 2025. We included in the study all patients with AV block who were received at the CEMECO clinic during the study period and who benefited from the insertion of a cardiac pacemaker. Result : We have identified 36 cases of AV Blockk out of 953 patients, 10 of whom benefited from the implantation of a pacemaker, representing an implantation rate of 27.78%. A male predominance was noted at 7/10 (70%) and the patients were aged 68 to 87 years. The symptomatology was marked by syncope 9/10 (90%) followed by exertional dyspnea 7/10 (70%). 9/10 (90%) of the cases were 3rd degree AV Blocks. The cephalic vein was the preferred route of access for 7/10 (70%) of our patients. Double chamber stimulation was the most practiced (8/10 cases, or 80%). All our patients had their clinical condition stabilized. In terms of complications, we noted a case of 1/10 (10%) of displacement of the atrial catheter, a case of 1/10 (10%) of pericardial tamponade that was well managed. Conclusion : The development of cardiac stimulation offers better prospects in the management of conductive disorders in our context. Measures to promote its accessibility should be considered.atrioventricular block; cardiac stimulation; guinea.
Functional mitral regurgitation (FMR) is associated with poor prognosis and increased morbidity in patients with left ventricular remodelling or atrial dilatation. The review is focused on the current evidence and guideline-based treatments for patients with FMR. Optimal management of patients with FMR requires early initiation and optimization of guideline-directed medical therapy (GDMT), evaluation of indication for cardiac resynchronization therapy (CRT), and timely evaluation for surgical or percutaneous intervention. A stepwise approach tailored to MR mechanism, ventricular geometry, and patient comorbidity is essential. In this paper we present a review on literature and a practical approach for the management of FMR based on currently available evidence.
Background/Aim The incidence of prosthetic valve thrombosis is rare, ranging from 0.1 to 5.7% patient/year, but represents a serious complication. Clinical manifestations are variable. Management is currently well codified but remains problematic in our countries due to the unavailability of emergency surgery and the lack of patient therapeutic education. The aim of our study was to evaluate the management of patients hospitalized for prosthetic heart valve thrombosis at the CHNU of FANN. Materials and Methods We conducted a cross-sectional, descriptive study from January 10, 2023 to January 10, 2025. All patients hospitalized for left-sided prosthetic heart valve thrombosis confirmed by transthoracic and/or transesophageal echocardiography and who received care at the CHNU of Fann were included. Results We collected 20 cases of prosthetic heart valve thrombosis, representing 3.27%. The mean age of patients was 32 ± 13 years with a sex ratio of 0.42. Mitral regurgitation was the leading cardiac condition (30%). Nineteen patients had a mechanical valve and one had a biological valve. Acenocoumarol was used in 85% of cases. PT-INR monitoring was irregular in 65% of cases. Therapeutic non-compliance was noted in 85% of cases. Symptoms were varied and dominated by dyspnea stage III/IV (NYHA) in 90% of cases. The prosthetic click was absent in 19 patients (100%). INR was below 2 in 55% of patients at the time of diagnosis. Mean mitral and aortic gradients were 22.84 mmHg and 70 mmHg, respectively. Therapeutically, thrombolysis was performed in 19 patients (95%) and redo surgery in 3 patients (15%). All patients were thrombolyzed with streptokinase with a success rate of 73.70%. The outcome was favorable in 75% of cases. Five deaths (25%) were recorded. Conclusion Prosthetic heart valve thrombosis, especially mechanical, was found predominantly in young subjects with a female predominance. The mitral prosthesis was the most affected. Poor therapeutic compliance and irregular follow-up were the main contributing factors. Thrombolysis was the treatment of choice in our context. Mortality remained significant.
Apolipoprotein C3 (ApoC3) is a glycoprotein that normally increases levels of plasma triglycerides. Thus, Apo C3 inhibitors such as olezarsen and plozasiran result in reduction of triglycerides levels. In 2 phase 3 clinical trials of patients having familial chylomicronemia syndrome (FCS), olezarsen 80 mg administered subcutaneously every 4 weeks decreased triglycerides by -43.5 % (95% CI, -69.1 to -17.9; P<0.001) after 6 months compared with placebo. Corresponding reduction with plozasiran 25 mg given every 3 months was -59% (95% CI, -90 to -28; P<0.001) after 10 months. In another 2 trials of patients with severe multifactorial chylomicronemia syndrome (MFS), the mean placebo-adjusted decreases in triglycerides levels ranged from 57% to 72% after 6 months of treatment with olezarsen and plozasiran. In previous studies, the 2 agents decreased incidence of acute pancreatitis by 82-85%. Olezarsen and plozasiran were generally well-tolerated. Yet, they cause mild worsening of glycemic control and increase levels of low-density lipoprotein-cholesterol (LDL-C). Olezarsen may also cause increase APOB levels in patients with FCS, mild thrombocytopenia and increase in hepatic fat. Olezarsen and plozasiran are the first drugs proved to substantially prevent hypertriglyceridemia-induced acute pancreatitis. Randomized trials are needed to establish their long-term efficacy and safety and their effects on cardiovascular (CV) outcomes and mortality.
Purpose: The study evaluated the treatment results of CABG and CABG with MVPprocedures for patients who had both moderate ischemic mitral regurgitation and coronary artery disease through mortality and morbidity and functional outcome assessments. Method: The research followed PRISMA-P 2015 guidelines through its database search of PubMed and Embase and Cochrane Library and Web of Science. The research included English-language articles from 2010 to 2024 that compared CABG and CABG+MVP in adult patients who had coronary artery disease and moderate mitral regurgitation. Results: The analysis included 12 studies with 11,168 patients. The effect size was 0.28 (95% CI: -0.20 to 0.44, p=0.47) in studies recommending CABG and 0.30 (95% CI: 0.07 to 0.15, p=0.01) in studies recommending MVP. The I² value was 24.36% (low heterogeneity) in the CABG group and 51.42% (high heterogeneity) in the MVP group. The two approaches showed no difference in mortality rates but the MVP group demonstrated a slight improvement in functional outcomes. Conclusion: The two surgical methods deliver satisfactory results for patients who have moderate ischemic mitral regurgitation. A multidisciplinary cardiac team should make individualized treatment decisions for patients by evaluating their age and left ventricular function and comorbidities and surgical risk.
Atrial septal defects (ASDs) are one of the most common congenital heart diseases and percutaneous closure has been shown to be safe and effective in closing defects in ”complex” conditions such as pulmonary arterial hypertension, association with coronary artery abnormalities and other heart malformations, lesions with multiple openings or rim deficiency and residual defects after previous surgical repair. In developing countries, FDA-approved devices are generally more expensive and sometimes unavailable, hence, the importance of reporting new devices is to include patients treated with other types of occlusors demonstrating adequate outcomes. A 50-year-old male weighing 90 kg was referred to our clinic for evaluation for percutaneous closure of a large ostium secundum type atrial septal defect. Transthoracic echocardiogram showed an ostium secundum type atrial septal defect measuring 29 × 27 mm in diameter, right atrial and right ventricular dilatation, and mild pulmonary arterial hypertension. A cardiac catheterization under general anesthesia was performed and a 36-mm Nit Occlud ASD-R “XL” device was implanted uneventfully under transesophageal echocardiographic guidance. To the best of our knowledge, this is the first report of transcatheter closure of large, isolated, secundum ASDs using successfully the new Nit Occlud ASD-R “XL” device.
The intricate relationship between oral health and cardiovascular disease represents one of the most compelling frontiers in modern medicine, challenging traditional disciplinary boundaries and demanding innovative approaches to patient care. This comprehensive review explores the profound connections between periodontal disease, oral infections and cardiovascular pathology, examining both established mechanisms and emerging therapeutic paradigms. We investigate the bidirectional nature of inflammatory mediators, the role of bacterial endocarditis in cardiovascular deterioration and novel biomarkers emerging from oral-cardiovascular cross-talk. Furthermore, we explore cutting-edge interventions including targeted antimicrobial therapies, anti-inflammatory approaches and interdisciplinary care models that integrate dental expertise into cardiovascular treatment pathways. The synthesis of precision medicine applications, artificial intelligence-driven diagnostics and minimally invasive interventions offers unprecedented opportunities to modify cardiovascular risk through oral health optimization. Our analysis suggests that future cardiovascular care paradigms must embrace the oral-systemic continuum with dental professionals positioned as essential members of cardiovascular care teams.
Among the various manifestations of electrocardiogram (ECG) for diagnosis of acute transmural myocardial infarction (ATMI), broad-based and tall tented T-waves, called hyperacute T-waves, may be the earliest and the only ECG sign of ATMI. As it is a rare ECG sign of ATMI, and because of its transient nature in the very early stage, quick identification of such ECG sign should trigger immediate evidence-based reperfusion therapeutic strategy to maximize myocardial salvage and survival of patients in the acute phase and in the long term. A male, 81 years of age with sudden onset typical ischemic chest pain, having history of chronic smoking, presented to the Heart Attack Centre (HAC) of SKY Hospital and Research Centre. The only ECG sign on presentation at the HAC was hyperacute T-wave changes in the chest leads, V2-V6. Cardiac injury marker (troponin T) done on presentation was normal. A simultaneously done bedside echocardiogram showed regional wall motion abnormality (RWMA) in the territory of left anterior descending (LAD) artery. Based on these findings, the patient was thrombolysed with intravenous (IV) tenecteplase with simultaneous administration of dual antiplatelet drugs and subcutaneous enoxaparin injection within 10 minutes of presentation to the HAC. His chest pain was completely relieved within minutes of the first-aid medication. Post-thrombolytic ECG showed near normalization of the T-wave changes. Subsequent coronary angiography showed 20% recanalization of proximal LAD artery obstruction which has probably helped save the myocardium in jeopardy and thereby reduced further damage of the myocardium. The culprit artery was stented with complete reperfusion of the affected myocardium.
Background: Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is a systemic immune-mediated vasculitis of unknown etiology. It predisposes to coronary artery disease. This study employs bidirectional Mendelian randomization (MR) to investigate interactions between KD and gut microbiota, thereby elucidating their causal relationships. Methods: Based on publicly available genome-wide association study (GWAS) data, genetic variants associated with gut microbiota and KD were selected as instrumental variables. Causal effects were assessed via inverse-variance weighted (IVW), weighted median (WM), and MR-Egger methods. Heterogeneity testing, sensitivity analyses, and pleiotropy evaluation were performed. Results: Forward MR analysis identified 14 microbial features with causal effects on KD, including: 5 protective taxa: e.g., OTU99_11 (Parabacteroides abundance) [OR: 0.351; 95% CI: 0.144–0.857; P = 0.022], 9 risk taxa: e.g., TestASV_42 (Alphaproteobacteria prevalence) [OR: 1.584; 95% CI: 1.046–2.397; P = 0.030]. Reverse MR (with KD as exposure) showed no significant causal effects on gut microbiota. Conclusion: Bidirectional two-sample MR demonstrates putative causal links between gut microbiota and KD, providing mechanistic insights for KD pathogenesis and therapeutic targeting.
Kounis syndrome is an increasingly recognized clinical entity characterized by the coexistence of acute coronary syndrome and allergic or hypersensitivity reactions. The syndrome represents the interaction between inflammatory pathways activated during allergic responses and the coronary circulation, leading to coronary vasospasm, plaque rupture, or coronary thrombosis. Various mediators released during mast cell activation, including histamine, leukotrienes, tryptase, and platelet-activating factor, play a central role in the pathophysiology by promoting vasoconstriction, endothelial dysfunction, platelet activation, and plaque destabilization. Although the condition has been reported in a wide range of clinical settings, its true incidence remains uncertain because it is frequently underdiagnosed or misinterpreted as either isolated anaphylaxis or conventional acute coronary syndrome. Kounis syndrome may be triggered by numerous allergens, most commonly drugs, insect stings, foods, and contrast media. Three clinical variants have been described depending on the underlying coronary anatomy and mechanism of injury: type I involving coronary vasospasm in patients with normal coronary arteries, type II occurring in individuals with preexisting atherosclerotic disease, and type III associated with coronary stent thrombosis. Clinical presentation is heterogeneous and may include chest pain, electrocardiographic changes, elevated cardiac biomarkers, and signs of systemic allergic reactions. Diagnosis relies on the integration of clinical history, laboratory findings, electrocardiography, and coronary imaging. Management requires simultaneous treatment of the allergic reaction and the acute coronary event, which can create therapeutic challenges. Identification and avoidance of triggering allergens are important for preventing recurrence. Increased awareness among clinicians is essential for early recognition and appropriate management. This review summarizes current knowledge regarding the epidemiology, pathophysiology, clinical manifestations, diagnostic strategies, and treatment approaches of Kounis syndrome.
Current algorithms for cardiovascular risk stratification rely heavily on traditional metabolic and behavioral metrics, frequently failing to capture the physiological toll of the macroenvironment. Amidst escalating global geopolitical unrest and targeted legislative hostility, the transgender and gender-diverse (TGD) community faces an unprecedented burden of systemic marginalization. This commentary explores how this specific sociopolitical climate acts as a potent catalyst for cardiovascular disease. By applying the Minority Stress Model to vascular pathophysiology, we delineate how chronic societal vigilance triggers profound autonomic dysregulation and hypothalamic-pituitary-adrenal (HPA) axis hyperactivity. This sustained neuroendocrine turbulence drives endothelial senescence, hypertension, and accelerated atherogenesis. We argue that clinical cardiology must urgently integrate structural determinants of health into routine risk assessments, recognizing that hostile geopolitics are not merely psychosocial issues, but primary drivers of cardiovascular morbidity.
Background: According to the World Stroke Organization (WSO) and the previous studies conducted by the Global Burden of Disease Analysis in 2021, it is estimated that there were 11.9 million incident strokes out of 93.8 million prevalent strokes. Hypertension was the main risk factor for stroke, contributing to around 90% cases [1]. To this risk factor, which subsequently requires adequate management, are added other clinical parameters such as the level of consciousness and the pyramidal deficit (Hemiparesis/hemiplegia), which also have a considerable impact on the prognosis of patients suffering from stroke. The situation gets worse when the focus shifts to sub-Saharan Africa. Following the example of Cameroon, where stroke outcome is characterized by high case fatality rates, with mortality rates around 25-30% within one month and over 30% within three months after a stroke event, and a particularly high recurrence rate. Methodology: We carried out a retrospective descriptive study over a period of one year going from the 01st of January 2024 to 31st December 2024 at the YEC. We used the emergency department registers and looked for all files of patients admitted at the YEC and treated for Stroke-like conditions. We excluded any incomplete patient files and all cases with clear alternative diagnoses that explained the neurological deficits. The extracted data were entered and managed using a generated Google sheet. The demographic characteristics of our population, the risk factors, the symptoms and signs, the clinical presentation, the imaging used, the different types of strokes found, the different vascular regions affected, the different treatment and the outcomes of patients were extracted into an excel file. From these, we focused our attention on elevated blood pressure, hemiparesis/hemiplegia and impaired consciousness as presentation. Then using R Studio we analyzed the relationship between these presentations and the patient outcome. Results: Impaired consciousness at presentation is the most powerful predictor of poor outcome in this cohort, with nearly half of affected patients dying during hospitalization. Hemiparesis is significantly associated with poorer recovery, reflecting more severe neurological injury. Elevated blood pressure at presentation is also significantly associated with outcome, suggesting a marker of systemic severity and possibly larger or more severe strokes. Overall, these results emphasize that neurological deficits and systemic severity markers at presentation are critical predictors of stroke outcome. Discussion: Patients with elevated blood pressure were more likely to fall into less favorable outcome categories, suggesting that elevated blood pressure could be an indicator of more severe neurological injury or systemic stress. The presence of hemiparesis/hemiplegia corresponded to a higher proportion of patients who either passed away or achieved only partial recovery. Clinically, motor impairment reflects early cortical or subcortical damage involving the corticospinal tracts and is closely correlated with infarct volume and location. Patients presenting with reduced consciousness had disproportionately high rates of mortality and poor recovery. A GCS score ≤8 was significantly associated with increased mortality and functional dependence. Conclusion: In acute stroke, elevated blood pressure, hemiparesis/hemiplegia, and impaired consciousness at presentation each have a statistically significant and moderate to strong association with patient outcomes. Impaired consciousness emerges as the most powerful predictor in this dataset. These findings support their continued use as rapid, bedside prognostic indicators and highlight the value of integrating simple clinical observations with formal outcome prediction models.
Cardiovascular diseases and neoplasms are closely interconnected, as each can stimulate or accelerate the development of the other. In particular, anticancer therapies that have significantly improved patient survival have also proven to be toxic—not only to the heart but to the entire cardiovascular system. It is therefore crucial to assess the risk of cardiotoxicity and to guide the patient throughout the entire course of treatment. In this context, the preparation of an accurate cardio-oncologic report is of paramount importance, as it facilitates the feasibility and safety of chemotherapy while minimizing the risk of preventable cardiovascular complications.
Textiles are used in heart monitoring by integrating conductive fibers and sensors directly into garments (e.g., shirts, straps, patches) to create comfortable, non-invasive, and continuous monitoring systems. These smart textiles capture physiological data like electrocardiogram (ECG) signals and heart rate, which can then be transmitted wirelessly for analysis.
